ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Arctic Bioscience Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.	Norway	ABS
ArcticZymes Technologies Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.	Norway	AZT
Arcturus Therapeutics Holdings Inc. Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.	United States of America	ARCT
Arcus Biosciences, Inc. A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.	United States of America	RCUS
Arcutis Biotherapeutics, Inc. Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.	United States of America	ARQT
ARDELYX, INC. Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.	United States of America	ARDX
ARECOR THERAPEUTICS PLC Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.	United Kingdom	AREC
argenx SE Develops first-in-class antibody therapies for severe autoimmune diseases.	Netherlands	1AE
ARGENX SE Develops antibody-based therapies for severe autoimmune diseases, including its lead drug VYVGART.	United States of America	ARGX
Armata Pharmaceuticals, Inc. Developing bacteriophage therapeutics for antibiotic-resistant infections.	United States of America	ARMP